One of the reasons Fangjyh Chern loves photography is because it allows her to capture a unique moment in time. For her, the fun and challenge comes from photographing instances that can never be truly reproduced or recreated. Since her own cancer diagnosis in 2014, Chern says she has had a heightened awareness of the … Continued
In their search for better treatments for breast, ovarian, and other cancers, young investigators Jennifer Guerriero, PhD, and Sarah Hill, MD, PhD, rely on a precious commodity — patient tissue samples obtained by surgeons in Dana-Farber’s Susan F. Smith Center for Women’s Cancers. Studies of these normal and cancerous tissues, which are collected, banked, and … Continued
In early 2019, Jess Skyleson found herself in a situation she never imagined she’d ever be in: telling a group of people what hope means to her. Less than a year ago, as she waded through her own cancer diagnosis, the idea of hope was the last thing Skyleson wanted to discuss. In 2018, she … Continued
Dana-Farber scientists recently uncovered a potential vulnerability in a form of ovarian cancer notoriously resistant to chemotherapy. Now they’ve opened a clinical trial involving a drug that targets that susceptibility in patients with the disease. The impetus for their research is a type of ovarian cancer with excess copies of the cyclinE1 gene (abbreviated CCNE1). … Continued
Medically reviewed by Alexander Gusev, PhD A team of Dana-Farber scientists and their associates has identified 34 genes associated with an increased risk of developing earliest-stage ovarian cancer. The findings, published in the journal Nature Genetics, will both help identify women who have the highest risk of developing ovarian cancer and pave the way for identifying … Continued
Medically reviewed by Kevin Elias, MD Today, cervical cancer is the only type of gynecologic cancer for which there is a routine screening test. The lack of such tests for endometrial and ovarian cancer — the most common gynecologic cancers — makes it especially important that women and their doctors be attuned to the symptoms … Continued
By Luisa Stigol, MD, FAAP I was a 74-year-old pediatrician in practice with a multi-specialty group associated with Boston Children’s Hospital. Forty years after becoming a doctor, I still loved learning new things and sharing them with my patients. Then I was diagnosed with ovarian cancer — and suddenly, a big wall separated me from … Continued
In the annals of patients who have benefited from Dana-Farber and Brigham and Women’s Hospital’s (BWH) genomic sequencing program Profile, few involve a turnabout as dramatic as one recently reported in Gynecologic Oncology. Authored by nearly a dozen Dana-Farber and BWH faculty, the paper recounts the medical history of a 49-year-old Nebraska woman first diagnosed … Continued
It was a bumpy road for Anne Sandstrom at first: after dealing with a stage IIIc ovarian cancer diagnosis, she had two relapses in a three-year span. But finally, treatment worked, and Sandstrom has enjoyed 16 years in which her disease lay dormant — enough for her oncologist to declare her “graduated” in 2017. The … Continued
Surgery is an essential component in the management of patients with gynecologic cancers. Surgical procedures may be utilized to initially diagnose cancers of the uterus, cervix, ovary, vulva and vagina. In addition, many gynecologic cancers are primarily treated (and often cured) with surgery alone. Nearly all gynecologic surgeries fall into either one of two categories: … Continued
Endometriosis is a non-cancerous disorder that occurs when tissue lining the inside of the uterus, known as the endometrium, appears in other parts of the body. It usually is found in the lower abdomen or pelvis but can appear in virtually any organ or tissue. Endometrial cancer, by contrast, occurs when cells in the endometrium … Continued
On the strength of the results of a major international clinical trial, there is now a new standard of care for patients with an advanced form of ovarian cancer who have responded to initial chemotherapy. The trial, dubbed SOLO-1, found that these patients – newly diagnosed with ovarian cancer that carries a mutation in the … Continued
In recent years, there has been a dearth of clinical trials studying new approaches to how endometrial cancer, which forms in the lining of the uterus, is treated. That is changing rapidly, however, as basic research into the disease spurs the testing of novel drugs and drug combinations. A host of clinical trials—including four led … Continued
Endometrial cancer — sometimes referred to as uterine cancer — is the most common cancer of the female reproductive organs. Mainly affecting postmenopausal women, endometrial cancer occurs when cancer cells form in the tissues of the endometrium, or the lining of the uterus. With early detection, endometrial cancer can be a highly curable cancer. While … Continued
It may not be sporting to hit someone when they’re down, but when the foe is a cancer cell, there’s no merit in mercy. That’s the principle behind drugs known as PARP inhibitors. Tumor cells that lack effective BRCA genes have difficulty repairing certain kinds of DNA damage, potentially leaving them vulnerable to agents that … Continued
Tests on living “organoids” created from patients’ ovarian cancer cells proved more accurate than DNA sequencing in predicting tumors’ sensitivity or resistance to chemotherapy drugs – and combining the two methods worked even better, say scientists at Dana-Farber Cancer Institute. The investigators report in Cancer Discovery that ovarian cancer organoids – tiny, three-dimensional spheres of cells … Continued
When Fran Austin’s ovarian cancer recurred after two rounds of chemotherapy, she found herself looking for a silver lining to the dark cloud of her disease. And she found it: Genetic profiling of her tumor identified her as an ideal candidate for an immunotherapy clinical trial, which has since shrunk her tumor by 60 percent … Continued
After two relapses, Janet Sheehan went on a clinical trial for her ovarian cancer. Four months later, her newest tumors were completely gone—and today, she’s relishing in a growing list of family milestones.
Julie Wisnia was undergoing treatment for ovarian cancer at Dana-Farber when she became inspired to participate in the Pan-Mass Challenge (PMC), a 163-mile bike-a-thon that raises funds for Dana-Farber.
Radiation therapy, or radiotherapy, is often one component of treatment for gynecologic malignancies such as cervical, vaginal, and endometrial cancer.
